X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 1c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q3 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $560 thousand versus the consensus estimate of $1.69 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Qtrex Quantum executives plan to buy up to 2M shares over 12 months
• H.C. Wainwright Reiterates Buy Rating on LB Pharmaceuticals Inc (LBRX)